Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Allakos Inc (ALLK)
NASDAQ:ALLK
ALLK Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.54 - $1.69
Previous CloseN/A
Volume85.32K
Average Volume (3M)725.28K
Market Cap
$108.11M
Enterprise Value$4.44M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.36
Next Earnings
Mar 04, 2025EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.03
Shares Outstanding89,343,636
10 Day Avg. Volume1,315,126
30 Day Avg. Volume725,282
Standard Deviation0.27
R-Squared0.03
Alpha-0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.90
P/FCF Ratio0.00
Enterprise Value/Market Cap0.04
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.72
Enterprise Value/Ebitda-0.03
Forecast
1Y Price Target
$0.30Price Target Upside25.00% Upside
Rating ConsensusHold
Number of Analyst Covering5
---
Bulls Say, Bears Say
Bulls Say
Competitive AdvantageTargeting Siglec-6 with AK006 may offer broader coverage than IgE targeted therapies, potentially providing a significant advantage.
Financial PerformanceWith ALLK shares trading at 3Q24 cash, the risk/reward into this data is favorable, especially when comparing to other smid-cap biotechs valued primarily on their CSU assets.
Investor InterestInvestors have shown significant interest in AK006, as it is a potent mast cell inhibitor, and it may provide broader coverage than IgE-targeted therapies.
Bears Say
Clinical TrialsAK006 failed to demonstrate therapeutic activity vs. placebo, and that further development of AK006 is being discontinued.
Financial OutlookThe company is expected to have an estimated $35M-$40M at June 30, 2025, compared to $81M at the end of 2024.
Workforce ReductionThe Allakos workforce is being reduced by approximately 75%.
---
Ownership Overview
9.23% Insiders
10.59% Mutual Funds
<0.01% Other Institutional Investors
75.63% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ALLK FAQ
What was Allakos Inc’s price range in the past 12 months?
Allakos Inc lowest stock price was $0.54 and its highest was $1.69 in the past 12 months.
What is Allakos Inc’s market cap?
Allakos Inc’s market cap is $108.11M.
When is Allakos Inc’s upcoming earnings report date?
Allakos Inc’s upcoming earnings report date is Mar 04, 2025 which is in 28 days.
How were Allakos Inc’s earnings last quarter?
Allakos Inc released its earnings results on Nov 06, 2024. The company reported -$0.21 earnings per share for the quarter, beating the consensus estimate of -$0.248 by $0.038.
Is Allakos Inc overvalued?
According to Wall Street analysts Allakos Inc’s price is currently Undervalued.
Does Allakos Inc pay dividends?
Allakos Inc does not currently pay dividends.
What is Allakos Inc’s EPS estimate?
Allakos Inc’s EPS estimate is -0.17.
How many shares outstanding does Allakos Inc have?
Allakos Inc has 89,343,636 shares outstanding.
What happened to Allakos Inc’s price movement after its last earnings report?
Allakos Inc reported an EPS of -$0.21 in its last earnings report, beating expectations of -$0.248. Following the earnings report the stock price went down -4.255%.
Which hedge fund is a major shareholder of Allakos Inc?
Among the largest hedge funds holding Allakos Inc’s share is Platinum Investment Management. It holds Allakos Inc’s shares valued at 692K.
---
Allakos Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$0.30 (25.00% Upside)
$0.30 (25.00% Upside)
Blogger Sentiment
Bearish
ALLK Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 33.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 7.7%
Last 30 Days ▲ 4.6%
Last 30 Days ▲ 4.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
4.31%
12-Months-Change
Fundamentals
Return on Equity
-121.68%
Trailing 12-Months
Asset Growth
-56.11%
Trailing 12-Months
Company Description
Allakos Inc
Allakos, Inc. engages in the development of therapeutic antibodies. Its primary product is AK002, a monoclonal antibody used for the treatment of various eosinophil and mast cell related diseases such as eosinophilic gastritis, urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis. The company was founded by Christopher Bebbington, Nenad Tomasevic, Bruce S. Bochner, and Robert Schleimer in 2012 and is headquartered in Redwood, CA.
---
ALLK Stock 12 Month Forecast
Average Price Target
$0.30
▲(25.00% Upside)
Technical Analysis
Adaptimmune Therapeutics
―
Crispr Therapeutics AG
―
AnaptysBio
―
Kiniksa Pharmaceuticals
―
Best Analysts Covering ALLK
1 Year
1 Year Success Rate
4/10 ratings generated profit
1 Year Average Return
-15.60%
assigned a buy rating 3 months ago
Copying Yasmeen Rahimi's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of -15.60% per trade.
---